Breast cancer molecular subtypes - Modern therapeutic concepts for targeted therapy of a heterogeneous entity

Cornelia Liedtke*, Ludwig Kiesel

*Corresponding author for this work
6 Citations (Scopus)

Abstract

Within the last decade, breast cancer is increasingly understood as a heterogeneous disease comprising distinct entities that vary significantly with regard to molecular biology and clinical features. Despite impressive advances in the treatment of patients with breast cancer, not all patients derive equal benefits from current therapeutic options and a significant number of patients still experience disease recurrence. Whereas for patients with hormone receptor positive and/or HER2/neu-positive breast cancer overcoming resistance against endocrine and/or anti-HER2/neu-targeted therapy is of particular importance, patients with triple negative breast cancer suffer from a lack of sufficient targeted therapeutic options at all. In this review we give a summary of the most important targeted agents recently or currently being developed for patients with breast cancer.

Original languageEnglish
JournalMaturitas
Volume73
Issue number4
Pages (from-to)288-294
Number of pages7
ISSN0378-5122
DOIs
Publication statusPublished - 01.12.2012

Fingerprint

Dive into the research topics of 'Breast cancer molecular subtypes - Modern therapeutic concepts for targeted therapy of a heterogeneous entity'. Together they form a unique fingerprint.

Cite this